Advertisements

Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus

Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus.....»»

Category: press-releasesSource: businesswireindiaJun 14th, 2017

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 20th, 2017

Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG

Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG.....»»

Category: press-releasesSource: businesswireindiaOct 18th, 2016

Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS

Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS.....»»

Category: press-releasesSource: businesswireindiaSep 17th, 2016

Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 28th, 2017

Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 28th, 2017

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation.....»»

Category: press-releasesSource: businesswireindiaJun 7th, 2017

European regulator EMA to review Biocon-Mylan’s version of insulin glargine

European regulator EMA to review Biocon-Mylan’s version of insulin glargine.....»»

Category: featuresSource: livemintNov 3rd, 2016

Glenmark Pharmaceuticals Announces Top-line Results From a Phase 3 Safety Study Evaluating Ryaltris in Patients With Perennial Allergic Rhinitis

Glenmark Pharmaceuticals Announces Top-line Results From a Phase 3 Safety Study Evaluating Ryaltris in Patients With Perennial Allergic Rhinitis.....»»

Category: press-releasesSource: prnewswireDec 14th, 2017

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®.....»»

Category: press-releasesSource: businesswireindiaNov 7th, 2017

Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD)

Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD).....»»

Category: press-releasesSource: businesswireindiaNov 2nd, 2017

Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trialat 18th World Conference on Lung Cancer

Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trialat 18th World Conference on Lung Cancer.....»»

Category: press-releasesSource: businesswireindiaSep 28th, 2017

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients.....»»

Category: press-releasesSource: businesswireindiaAug 23rd, 2017

Glenmark’s dermatitis molecule displays positive results in phase-2a trial

Glenmark’s dermatitis molecule displays positive results in phase-2a trial.....»»

Category: featuresSource: livemintAug 1st, 2017

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting.....»»

Category: press-releasesSource: businesswireindiaJun 24th, 2017

Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy

Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy.....»»

Category: press-releasesSource: businesswireindiaMar 5th, 2017

ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations

ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations.....»»

Category: press-releasesSource: businesswireindiaDec 6th, 2016

Updated Phase III Results Reinforce Safety and Efficacy of Praxbind® (idarucizumab) in Urgent Situations

Updated Phase III Results Reinforce Safety and Efficacy of Praxbind® (idarucizumab) in Urgent Situations.....»»

Category: press-releasesSource: businesswireindiaNov 16th, 2016

Data on Early Onset of Efficacy for Oral OTEZLA® (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology

Data on Early Onset of Efficacy for Oral OTEZLA® (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology.....»»

Category: press-releasesSource: businesswireindiaNov 14th, 2016

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study.....»»

Category: press-releasesSource: businesswireindiaOct 27th, 2016

J P Nadda assures support for treatment of fire-hit patients

J P Nadda assures support for treatment of fire-hit patients.....»»

Category: economySource: business-standardOct 19th, 2016